Insider Selling: Stryker Co. (NYSE:SYK) COO Sells 4,666 Shares of Stock

Stryker Co. (NYSE:SYK) COO Timothy J. Scannell sold 4,666 shares of the stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $218.51, for a total transaction of $1,019,567.66. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Timothy J. Scannell also recently made the following trade(s):

  • On Friday, August 16th, Timothy J. Scannell sold 4,666 shares of Stryker stock. The stock was sold at an average price of $217.08, for a total transaction of $1,012,895.28.

Shares of SYK traded up $2.52 during midday trading on Friday, reaching $213.81. The stock had a trading volume of 770,049 shares, compared to its average volume of 1,151,058. Stryker Co. has a 1-year low of $144.75 and a 1-year high of $223.45. The company’s fifty day simple moving average is $216.98 and its two-hundred day simple moving average is $203.00. The company has a market cap of $78.89 billion, a price-to-earnings ratio of 29.25, a PEG ratio of 2.56 and a beta of 0.81. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.07 and a quick ratio of 1.26.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 25th. The medical technology company reported $1.98 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.93 by $0.05. Stryker had a net margin of 24.99% and a return on equity of 25.98%. The business had revenue of $3.65 billion for the quarter, compared to analyst estimates of $3.60 billion. During the same period last year, the business earned $1.76 EPS. The company’s revenue was up 9.9% on a year-over-year basis. On average, sell-side analysts forecast that Stryker Co. will post 8.21 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 31st. Investors of record on Monday, September 30th will be paid a dividend of $0.52 per share. The ex-dividend date is Friday, September 27th. This represents a $2.08 annualized dividend and a yield of 0.97%. Stryker’s dividend payout ratio is currently 28.45%.

A number of equities analysts recently weighed in on SYK shares. Morgan Stanley increased their price objective on shares of Stryker from $218.00 to $230.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 16th. ValuEngine cut shares of Stryker from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Canaccord Genuity increased their price objective on shares of Stryker from $195.00 to $233.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Zacks Investment Research raised shares of Stryker from a “hold” rating to a “buy” rating and set a $225.00 price objective for the company in a research report on Monday, July 29th. Finally, Svb Leerink reaffirmed an “outperform” rating on shares of Stryker in a research report on Wednesday, July 10th. Six investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Stryker currently has a consensus rating of “Buy” and a consensus target price of $214.89.

A number of large investors have recently made changes to their positions in SYK. Nuveen Asset Management LLC raised its stake in Stryker by 20,218.6% during the 2nd quarter. Nuveen Asset Management LLC now owns 2,596,110 shares of the medical technology company’s stock worth $533,708,000 after acquiring an additional 2,583,333 shares in the last quarter. FMR LLC increased its stake in Stryker by 13.4% in the first quarter. FMR LLC now owns 6,728,182 shares of the medical technology company’s stock valued at $1,328,951,000 after purchasing an additional 793,560 shares during the period. Vanguard Group Inc. increased its stake in Stryker by 2.1% in the second quarter. Vanguard Group Inc. now owns 26,735,288 shares of the medical technology company’s stock valued at $5,496,241,000 after purchasing an additional 555,327 shares during the period. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in Stryker in the second quarter valued at $60,571,000. Finally, GQG Partners LLC increased its stake in Stryker by 24.8% in the first quarter. GQG Partners LLC now owns 924,369 shares of the medical technology company’s stock valued at $182,241,000 after purchasing an additional 183,802 shares during the period. Hedge funds and other institutional investors own 72.95% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

See Also: Index Funds

Insider Buying and Selling by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.